Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in Cardiac Sarcoidosis (RESOLVE-Heart)
NCT05351554Phase 2Terminated
- Sponsor
- Kinevant Sciences
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of namilumab in cardiac sarcoidosis (CS), sponsored by Kinevant Sciences. Started Aug 2022; status: terminated.
02
Drugs
namilumab
03
Conditions
cardiac sarcoidosis (CS)
Beyond the preview
Go deeper on NCT05351554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351554.